UNSPSC 51101908: Artemether

This classification denotes an antimalarial agent with the molecular formula C16H26O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7D6T3H22J, chemically known as 3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12ar)-, (+)- but generally known as artemether, which bears US NIH Compound Identifier 68911. European Medicines Agency schedules Artemether in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05574MIG.

UNSPSC 51101908 Artemether is a Commodity code, but the recent state and local opportunities tagged under it diverge sharply from the code's nominal scope. The four recent solicitations involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products—none of which are artemether, an antimalarial pharmaceutical. The mismatch suggests either tagging error at the source or a broad interpretation of pharmaceutical procurement that does not align cleanly with the code's intended commodity.

The issuing bodies span state health and human services commissions, county health departments, city fire departments, and multi-state cooperative purchasing alliances. The Minnesota Department of Administration's Office of State Procurement issued an RFP for generic pharmaceuticals and OTC products through the MMCAP cooperative vehicle with a response date of March 26, 2026; Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS with a response deadline of July 26, 2023 (noted as substantially outdated); the City of Tampa's Purchasing Department issued an IFB for medical and first aid supplies for the Tampa Fire Department Rescue Division with a March 13, 2026 response date and an estimated contract value of $700,000; and the Texas Health and Human Services Commission issued an RFI for direct-to-manufacturer prescription program capabilities with an April 3, 2026 response deadline. Activity is concentrated in Florida, Minnesota, Texas, and the broader multi-state cooperative network. The code shows little relevant recent activity aligned with artemether procurement specifically.